Krystal Biotech Offers Good Prospects Amid Pipeline Delays, RBC Says

12:08 PM EST, 11/03/2026 (MT Newswires) -- Krystal Biotech (KRYS) is still offering good prospects amid pipeline delays, including in neurotrophic keratitis, RBC Capital Markets said in a note Monday. The report said the pipeline delays are unfortunate, but the company may be cutting it too close on clinical trial enrollment in favor of keeping operational efficiencies. "Given KRYS is functioning in areas with no approved treatments (CF), limited competition (ocular DEB), or a clear convenience advantage (NK), we ultimately do not think these delays will significantly impact the commercial opp.," the note said. The note said careful patient selection will pay off down the line. "We would rather see slow-enrollment of the right patients vs fast-enrollment of the wrong patients," it said. RBC reiterated its outperform rating while lowering its price target to $375 from $400. Price: 300.13, Change: +4.23, Percent Change: +1.43